Belite Bio Inc
BLTE
$38.38
Closing
▲2.98%
1D
▼-16.11%
YTD
Market cap
$1.13B
52 week high
$48.50
52 week low
$11.05
Volume
3,009
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$1.13B
Analysts' Rating
BUY
Price Target (Mean)
51
Total Analysts
4
P/E
Operating Margin
0.00%
Beta
Revenue Growth (Annual)
0.00%
52 week high
$48.50
52 week low
$11.05
Div. Yield
%
EPS Annual Growth
53.85
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on therapeutics targeting untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration (dry AMD) and autosomal recessive Stargardt disease (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. The Company is developing LBS-008 as an oral daily treatment for STGD1 and dry AMD. LBS-008 is a therapy targeting dry AMD and STGD1, which are untreatable conditions that cause progressive vision loss in affected individuals. LBS-008 is an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A (retinol) to the eye. The Company’s LBS-009 is an anti-Retinol binding protein 4 (RBP4) oral therapy targeting liver disease, including NAFLD, NASH, and T2D.
